Our study extends the results of a phase III trial in non-small cell lung cancer patients with adenocarcinomas harboring EML4-ALK fusion. We performed a co-clinical trial in a mouse model comparing the ALK inhibitor crizotinib to the standard-of-care agents docetaxel or pemetrexed. Concordant with the clinical outcome in humans, crizotinib produced a higher response rate compared to chemotherapy, associated with significantly longer progression-free and overall survival. We also demonstrated that pemetrexed produced superior overall survival compared to docetaxel. Additionally, in the EML4-ALK-driven mouse lung adenocarcinoma model, HSP90 inhibition can overcome both primary and acquired crizotinib resistance. Furthermore, HSP90 inhibition as well as a second-generation ALK inhibitor, TAE684, demonstrated activity in lung adenocarcinoma models driven by crizotinib-insensitive EML4-ALK L1196M or F1174L. Our findings suggest that crizotinib is superior to standard chemotherapy in ALK inhibitor-naïve disease and support clinical investigation of HSP90 inhibitors and second-generation ALK inhibitors in tumors with primary or acquired crizotinib resistance.
Introduction
EML4-ALK fusion accounts for approximately 4% of non-small cell lung cancer (NSCLC) (1, 2) . Crizotnib (3, 4) , an FDA-approved inhibitor of anaplastic lymphoma kinase (ALK), demonstrated efficacy in a phase II clinical trial in lung cancer patients with tumors harboring EML4-ALK rearrangements (5) . Despite striking activity in early studies, some reports have also noted impressive activity with chemotherapy in ALK-positive cancers (6, 7) . Indeed, retrospective analyses have suggested that time to progression on crizotinib is statistically similar to that achieved by first-line platinum-based chemotherapy (2, 8, 9 ). Thus, it was unclear if crizotinib is superior to either first or second line chemotherapy in this subset of patients. These uncertainties were recently addressed by a phase III trial comparing crizotinib to chemotherapies in the second-line setting that definitively demonstrated the superiority of crizotinib (10).
Nonetheless, both primary and acquired resistance have been observed in patients treated with crizotinib (11-14). Up to 30% ALK-positive patients do not respond to crizotinib treatment, while those who respond initially will eventually develop acquired resistance after prolonged treatment. Secondary mutations in the ALK kinase domain have been identified in a subset of patients who become insensitive to crizotinib.
Co-clinical trials, in which highly faithful genetically engineered murine cancer models (GEMMs) are carefully randomized and used to mimic human clinical trials, have the potential to provide mechanistic insights that impact the analysis of the concurrent human study (15) (16) (17) (18) (19) (20) . In recent years, we and others have performed numerous treatment studies in GEMMs leading to identification of clinically relevant biomarkers and novel treatment methods, as well as successful prediction of clinical outcomes (21) (22) (23) (24) (25) (26) . In particular, we have previously described a co-clinical trial using a murine model recapitulating human NSCLC driven by an activating Kras mutation In the present analysis, we have performed a murine co-clinical study mimicking the phase III clinical trial in ALK-positive patients with advanced disease who had received prior platinum-doublet-based first-line treatment. In this study, patients were randomized to receive crizotinib or standard second-line therapy, including docetaxel or pemetrexed. Using novel murine models of EML4-ALK NSCLC, we determined the short-and long-term efficacy of crizotinib treatment compared to docetaxel or pemetrexed. The results demonstrate the predictive power of EML4-ALK-driven murine lung adenocarcinoma models and validate their use for studying additional treatments for the ALK population. Toward this end, we explored treatment with an HSP90 inhibitor and a second-generation ALK inhibitor to overcome either primary or acquired crizotinib resistance in order to anticipate their roles in the growing ALK armamentarium. 7 operators, Bland-Altman analysis was performed based on quantification results from the two operators on a total of sixteen MRI scan images, as previously described (21) , and adapted in this study. Progressive disease (PD) was defined as a >30% tumor burden increase compared to baseline. Partial response (PR) was defined as a >30% decrease in tumor burden compared to baseline. Mice having tumor burden changes within +/-30% of baseline were considered to have stable disease (SD). Overall survival (OS) was assessed with endpoints of death or moribund condition.
Progression-free survival (PFS) was defined as the time to tumor re-growth exceeding 20% of the lowest tumor burden achieved after initial treatment, development of moribund condition or death.
Immunohistochemistry
Antibodies recognizing phospho-Akt (Ser473), and phospho-S6 (Thr389) were obtained from Cell Signaling Technology. Phospho-ERK1/2 (pT185/pY187) antibodies was purchased from Biosource International. Tissue processing and immunohistochemistry (IHC) were performed on tumor samples as previously described (21) . To quantify IHC, staining intensity (0-4+) was assessed for 10 microscopic fields, and an average value was derived.
Results
Crizotinib improves initial response of EML4-ALK lung cancer compared to standard-of-care therapy.
In an effort to determine sensitivity to commonly used chemotherapeutics, a large cohort of EML-ALK mice was generated and serially observed for tumor formation as previously described (28). One group of tumor-bearing mice was treated with 50 mg/kg/day crizotinib for 2 weeks, which led to stable disease, but did not result in tumor regression (Fig. 1A, Supplemental Figure 1 mg/kg/day in the majority of animals (Fig. 1B, Supplemental Fig. 1 ) with a high rate of partial response (68%; defined as >30% tumor regression) or stable disease (23%).
These results indicate that the response of ALK-driven tumors to crizotinib may be dose-dependent and suggest that insufficient ALK inhibition may be one of the mechanisms for primary crizotinib resistance observed clinically. Notably, even at 100 mg/kg/day, very few mice (2/22) achieved near-complete remission (>90% tumor regression). Also of note, 2 of 22 mice exhibited primary resistance (Fig. 1B,   Supplemental Fig. 1B) . Consistent with the known mechanism of action (28), phospho-ERK, phospho-Akt, phospho-S6, and Stat3 protein expression were reduced in crizotinib-treated tumors (Fig. 1C) . Taken together, these data show that crizotinib is highly active in a faithful murine model of ALK-driven NSCLC.
The activity of cytotoxic agents was less impressive: no mice treated with docetaxel achieved partial response, but this outcome was achieved with 2 out of 8 mice treated with pemetrexed (Fig. 1B) . However, both docetaxel and pemtrexed produced disease stabilization ( Fig. 1D ). Of note, using the commonly applied "disease control rate" (DCR) metric of complete response + partial response + stable disease (CR+PR+SD), the three study arms appeared comparable (Fig. 1D ). These data recapitulate clinical results showing similar rate of disease control between crizotinib and plantinum-based chemotherapy.
Nonetheless, the objective response rate to crizotinib was significantly higher than with docetaxel or pemetrexed (p<0.0005, t test), similar to what has been observed in patients with ALK-rearranged lung cancer and confirming the utility of this model to predict clinical outcome.
Prior work in GEMMs has clearly shown that tumor response does not necessarily translate into enhanced long-term survival (23) . To establish the effects of crizotinib, docetaxel and pemetrexed on overall and progression-free survival, cohorts of tumor-bearing mice were followed on therapy until progression or to overall survival endpoints. The median survival on crizotinib was more than 17 weeks after treatment initiation, versus only 4.3 weeks in the docetaxel arm ( Fig. 2A) . Time to 3A ). In contrast, treatment with 17-DMAG reduced FDG uptake in all tumors, and the magnitude of suppression was significantly greater in 17-DMAG-treated animals compared to crizotinib (Fig. 3B) . Importantly, in animals treated with a brief exposure to crizotinib, immediate cross-over to treatment with 17-DMAG eliminated all residual 18 F-FDG uptake, suggesting that HSP90 inhibition may eradicate cell populations with primary crizotinib resistance (Fig. 3C ).
To study whether HSP90 inhibition is efficacious in the setting of acquired resistance
Research. conferred by secondary kinase domain mutations identified in patients(11, 12), we developed another genetically-engineered mouse strain carrying an EML4-ALK fusion oncogene with a clinically-relevant L1196M gatekeeper mutation that confers resistance to crizotinib. Treatment for two weeks with 17-DMAG led to complete tumor regression (Fig. 4A) .
Similarly, four tumor-bearing mice that harbor a different mutation, EML4-ALK F1174L, also exhibited significant tumor reduction when treated with 17-DMAG, with TTP ranging from 6 to 11 weeks (Fig. 4B) , a duration similar to the response seen to 17-DMAG in native EML4-ALK mice (unpublished results). We also evaluated TAE684, a highly potent second-generation ALK inhibitor that retains in vitro activity in the presence of secondary mutations that confer crizotinib resistance (24) . As with 17-DMAG, treatment with TAE684 also led to complete tumor regression in the EML4-ALK L1196M model (Fig. 4A ).
We next investigated whether TAE684 can overcome crizotinib and 17-DMAG acquired resistance in both native EML4-ALK mice and EML4-ALK F1174L mutants.
First, we treated native EML4-ALK mice with 17-DMAG until tumor re-growth occurred, indicated by rebound of 18 F-FDG uptake on PET-CT. Subsequent treatment with TAE684 in these mice resulted in potent re-suppression of 18 F-FDG uptake, indicating TAE684 can be used to circumvent resistance to HSP90 inhibitors in native ALK tumors (Fig. 4C) . Similarly, when TAE684 was administered to the four EML4-ALK F1174L mice that had developed resistance to long-term 17-DMAG treatment, significant tumor regression was observed, as measured by changes in tumor burden on MRI (Fig. 4B) . Surprisingly, however, 3 of the 4 mice experienced relapse soon after the initial response to TAE684, with TTP ranging from 3 to 11 weeks ( Fig. 4B and Supplemental Fig. 2) ; the fourth mouse died one day after switching to TAE684 from unknown causes. The short TTP in these mice contrasts with our previous results in treatment-naïve native EML4-ALK mice that remained free of tumor recurrence for almost 2 years after an initial response to daily administration of TAE684(28 (Fig. 4D) . We also confirmed that these mice remain resistant to 17-DMAG. Interestingly, however, a 10-day treatment with the combination of 17-DMAG and TAE684 successfully eliminated most of these tumors that were resistant to either TAE684 or 17-DMAG as single agents (Supplemental Fig. 3 ).
Collectively, these results suggest that HSP90 inhibition may be a viable option for treating tumors with primary or acquired crizotinib resistance.
Second-generation ALK inhibitors represent another strategy, but may exhibit reduced efficacy against tumors carrying secondary mutations conferring crizotinib resistance, compared to the long-term benefit seen when they are used in the setting of de novo treatment of native EML4-ALK tumors.
Discussion
Recently, development of numerous target-specific small molecule inhibitors and antibodies has resulted in improved anti-tumor responses with fewer adverse events than standard-of-care cytotoxic chemotherapy. Clinical application of these therapeutic agents is generally limited by the need for lengthy clinical trials to assure their safety and efficacy. Additionally, this process is complicated by newer patient stratification criteria and combination therapy strategies. However, the implementation of co-clinical trials promises to speed drug development by improving evaluation of treatments and better matching them to disease subtypes.
Using a well-defined murine EML4-ALK lung cancer model, we demonstrate that crizotinib is superior to the conventional chemotherapy agents docetaxel and pemetrexed in terms of response and survival. Docetaxel treatment did not result in any tumor regression, whereas pemetrexed offered a modest survival benefit over docetaxel, producing a few partial responses. Thus, while a subset of ALK-driven tumors may respond to pemetrexed treatment, crizotinib appears a better choice.
We also noted primary resistance to crizotinib in EML4-ALK tumors, as found in We have also evaluated the second-generation ALK inhibitor TAE684 in our models.
Many of the altered residues that cause crizotinib resistance do not exhibit a significant role in binding of second-generation ALK inhibitors such as TAE684 and AP26113, which differ in chemical structure from crizotinib. Consequently, many crizotinib-resistant mutants remain sensitive to second-generation inhibitors in cell line assays, albeit at reduced potency compared to native ALK (12, 14). Among these secondary mutations, the ALK F1174L mutant confers both enhanced oncogenic potency and decreased crizotinib affinity (14). We have shown that the enhanced in vitro profile of TAE684 translates into response in mice genetically engineered to harbor the EML4-ALK F1174L mutation, even in the setting of resistance to 17-DMAG. However, responses in resistant tumors were short-lived. Although EML4-ALK F1174L is inhibited by TAE684, its sensitivity in vitro is 10-fold less than that of native ALK(14). We propose that the combination of reduced drug potency against ALK proteins carrying the secondary F1174L mutation, as well as the increased oncogenic activity conferred by this mutation, affects the response to TAE684. These results suggest that inhibitors specific for individual secondary mutations may improve efficacy in the crizotinib-resistant setting.
In addition, considering the superior durability of response to TAE684 in crizotinib-naïve vs.
resistant tumors, use of the more potent ALK inhibitor as first-line treatment may better delay the development of additional resistance mutations than the current sequence in which the weak inhibitor, crizotinib, precedes use of the more potent agent. Although TAE684 is not being developed clinically, the related LDK378 has 
